Proteus Digital Health today said the FDA expanded the indications for use for its sensor-enabled pill technology, claiming it as the only FDA-approved device designed to measure medication adherence.
“We are delighted that our collaborative work with the FDA continues to enable positive progress,” co-founder & chief medical officer Dr. George Savage said in prepared remarks. “We believe that ingestible devices have the potential to speed clinical trials and improve the real-world effectiveness of medicines in community settings.”
Redwood Shores, Calif.-based Proteus said its ingestible sensor logs actual intake time as a quantifiable event, communicating with an adhesive patch worn on the torso.
A year ago Proteus drummed up a $172 million Series G round. Although the company didn’t provide details on that funding, previous backers include Medtronic (NYSE:MDT), Novartis (NYSE:NVS), Kaiser Permanente and others.